Stockreport

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage [Read more]